To know more about Age-related Macular Degeneration, please click here.

Macular degeneration

Ophthotech Fovista AMD Phase 3 trials results come up short

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Eylea® (aflibercept) or Avastin® (bevacizumab) anti-VEGF therapy compared to Eylea or Avastin monotherapy for the treatment of

READ MORE…

AMD

High rate of undiagnosed age-related macular degeneration (AMD) in primary eye care practices

A study finds high rate of underdiagnosis of age-related macular degeneration in primary eye care practices and advocates need for improved detection strategies. Age-related macular degeneration (AMD) is the leading cause of irreversible vision impairment in older adults in the United States, yet little is known about whether AMD is appropriately diagnosed in primary eye

READ MORE…

Diabetic Retinopathy

Researchers identify new target for abnormal blood vessel growth in the eyes

A team led by Massachusetts Eye and Ear researchers has identified a novel therapeutic target for retinal neovascularization, or abnormal blood vessel growth in the retina, a hallmark of advanced diabetic eye disease. According to a report published online in Diabetes, the transcription factor RUNX1 was found in abnormal retinal blood vessels, and by inhibiting

READ MORE…

Cone-rod dystrophy

Researchers find causative factors in retinal dystrophies

Scientists from the Florida campus of The Scripps Research Institute have discovered how a protein called α2δ4 establishes proper vision. Their research helps explain why mutations in the gene encoding α2δ4 lead to retinal dystrophy, a disease characterized by defective color vision and night blindness. To study how this protein supports vision, the researchers modeled

READ MORE…

(c) Ophthotech

Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista ® in Wet AMD

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating superiority of Fovista (pegpleranib) anti-PDGF therapy in combination with Lucentis (ranibizumab) anti-VEGF therapy compared to Lucentis monotherapy for the treatment of wet age-related macular degeneration

READ MORE…

Surgery in monkey eye

Stem-cell derived retina found to improve vision in monkeys with RP

Researchers at the RIKEN Institute in Japan have succeeded in growing human embryonic stem cell-derived retina (hESC-retina) and transplanting that tissue into the retinas of rhesus monkeys with Retinitis Pigmentosa (RP). Three weeks after the treatment, visual tests on two of the monkeys found their vision had improved. In the study, published in the journal PNAS,

READ MORE…

Laser gene delivery system

A gene therapy platform for macular degeneration patients

Physics researchers at The University of Texas at Arlington have developed a new platform that uses ultrafast near-infrared lasers to deliver gene therapy to damaged areas of the retina to enable vision restoration in patients with photo-degenerative diseases such as macular degeneration. Samarenda Mohanty, assistant professor of physics and head of UTA’s Biophysics and Physiology

READ MORE…

Patients waiting for an eye exam

Visit to Cochabamba, Bolivia

This visit was supported by a grant from Alcon Foundation. As part of our outreach into South America, we visited Cochabamba in Bolivia the week of Oct 26, 2015. We are collaborating with the Fundación Boliviana de Oftalmología to help develop retinal services in the country. Dr Oscar Cortex and his son, Dr Rodrigo Cortes, manage this

READ MORE…

Ocular gene therapy

Gene therapy for neovascular age-related macular degeneration safe at 1 year

Results from a single-center, phase 1, randomized controlled clinical trial show that ocular gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration was found to be safe and well tolerated. The study enrolled patients with wet age-related macular degeneration at the Lions Eye Institute and the Sir Charles Gairdner Hospital in Nedlands, WA, Australia. Eligible

READ MORE…